Oppenheimer Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Oppenheimer Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$813K	Sell	21,723 -7	-0%	-$260	0.01%	780
2026 Q1	$789K	Buy	21,730 +3,944	+22%	+$176K	0.01%	780
2025 Q4	$828K	Buy	17,786 +12,489	+236%	+$556K	0.01%	718
2025 Q3	$221K	Buy	+5,297	New	+$169K	﹤0.01%	1074
2025 Q1	–	Sell	-5,038	Closed	-$258K	–	1140
2024 Q4	$258K	Buy	5,038 +822	+19%	+$46K	﹤0.01%	1018
2024 Q3	$215K	Buy	+4,216	New	+$217K	﹤0.01%	1082
2024 Q2	–	Sell	-4,276	Closed	-$200K	–	1156
2024 Q1	$200K	Buy	+4,276	New	+$167K	﹤0.01%	1039

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Oppenheimer Asset Management's CRNX Position: Q2 2026 in Review

Oppenheimer Asset Management reduced its Crinetics Pharmaceuticals (CRNX) stake by 0.03% in Q2 2026, selling an estimated $260 and leaving 21,723 shares worth $813K. The position accounts for 0.01% of the portfolio, ranked #780.

Oppenheimer Asset Management first reported a position in CRNX in Q1 2024 and has held it in 7 quarters since. The position peaked at $828K in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Oppenheimer Asset Management held 21,723 shares of Crinetics Pharmaceuticals worth $813K as of Q2 2026.
Oppenheimer Asset Management sold 7 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $260.
Crinetics Pharmaceuticals made up 0.01% of Oppenheimer Asset Management's portfolio in Q2 2026, its #780 holding.
Oppenheimer Asset Management first reported a position in Crinetics Pharmaceuticals in Q1 2024 and has held it in 7 quarters since.
Oppenheimer Asset Management's Crinetics Pharmaceuticals position peaked at $828K in Q4 2025.
267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Oppenheimer Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.